Chiesi Limited is part of Chiesi Group, based in Parma, Italy.
Chiesi Farmaceutici is an international research-oriented group with over 80 years’ experience in the pharmaceutical sector, and is present in 29 countries including the UK. The group researches, develops and commercialises innovative medicines in respiratory disease, special care and rare disease therapeutic areas.
Chiesi Group is different to many pharmaceutical companies, not just because it is a family owned company, but because it is the largest pharmaceutical company to date with B Corp® certification.
Find out more about Chiesi’s sustainability journey here.
Chiesi in cystic fibrosis (CF)
Chiesi has been developing respiratory medicines for more than 30 years. CF is part of our Special Care business unit which also includes Neonatology and Transplantation. Chiesi are also expanding into medicines for other rare diseases.
Chiesi are committed to supporting CF specialists and their patients, in the UK and Ireland, through various CF initiatives.
A continually ageing CF population presents the challenge of needing more treatment options to help maintain good health for longer.1,2
At Chiesi, we are committed to tackling the continuing challenges of the management of CF, by providing medicines which aim to protect lung health, particularly through adulthood.
Chiesi’s CF portfolio currently contains three products:
– A mucolytic which is a medicine which aims to aid mucus clearance from the lungs.
– Two different inhaled antibiotics for the management of chronic lung infections caused by the bacteria Pseudomonas aeruginosa.
If you’re someone who has been prescribed a Chiesi CF Medicine, or their carer, you can find out more about our medicines here.
- Geller et al. 2011. Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects
- Flume et al. 2016. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
IE-CF-2000180 | Nov 2020